Hepatitis Research and Treatment

Clinical Study

Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks

Table 4

Area under the receiver operating characteristic curve according to significant predicting factors for sustained virological response.
FactorsAUC95% CI
Non-NR to prior PEG-IFN and ribavirin0.6950.1180.441–0.949
IL28B major 0.8130.0120.632–0.994
Core 70 wild 0.7690.0320.577–0.960
Cirrhosis0.7550.0410.563–0.948
Hyaluronic acid level0.7470.0480.515–0.979
Reduction of HCV-RNA at week 1 0.8490.0050.682–1.000
Reduction of HCV-RNA at week 2 0.8570.0040.716–0.999
Reduction of HCV-RNA at week 4 0.8130.0120.663–0.963
RVR0.7420.0530.524–0.905
AUC, area under the receiver operating characteristic curve; CI, confidence interval; NR, no response; PEG-IFN, pegylated interferon; IL, interleukin; HCV, hepatitis C virus; RVR, rapid virological response.